PBYI
Puma Biotechnology, Inc. NASDAQ Listed Apr 24, 2012$7.25
After hrs
$7.49
+0.00%
Mkt Cap $369.0M
52w Low $2.85
87.1% of range
52w High $7.90
50d MA $6.83
200d MA $5.70
P/E (TTM)
12.1x
EV/EBITDA
5.6x
P/B
2.9x
Debt/Equity
0.2x
ROE
23.9%
P/FCF
7.1x
RSI (14)
—
ATR (14)
—
Beta
1.18
50d MA
$6.83
200d MA
$5.70
Avg Volume
369.0K
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for the use of neratinib in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer; PB272 (neratinib, oral) for HER2 mutation-positive solid tumors. It has a license agreement with Pfizer, Inc.; and sub-license agreement with Specialised Therapeutics Asia Pte Ltd., CANbridge BIOMED Limited, Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.
10880 Wilshire Boulevard · Los Angeles, CA 90024 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 26, 2026 | AMC | 0.24 | 0.29 | +20.8% | 7.60 | -17.1% | -25.0% | -15.5% | -18.3% | -15.8% | -18.0% | — |
| Nov 6, 2025 | AMC | 0.09 | 0.21 | +133.3% | 4.90 | +8.8% | +22.2% | -3.5% | +5.9% | +1.8% | +1.0% | — |
| Aug 7, 2025 | AMC | 0.11 | 0.15 | +36.4% | 3.29 | -7.3% | +12.2% | +47.4% | +48.0% | +61.1% | +61.7% | — |
| May 8, 2025 | AMC | 0.02 | 0.10 | +400.0% | 3.07 | +1.3% | -5.2% | -1.0% | -2.0% | -5.5% | +6.8% | — |
| Feb 27, 2025 | AMC | 0.10 | 0.43 | +330.0% | 2.99 | +3.3% | +19.7% | +12.0% | +13.4% | +18.4% | +21.1% | — |
| Nov 7, 2024 | AMC | 0.35 | 0.41 | +17.1% | 3.03 | +11.9% | -5.0% | +8.9% | +5.9% | -2.0% | -1.3% | — |
| Aug 1, 2024 | AMC | -0.10 | -0.05 | +50.0% | 3.50 | -6.3% | +9.4% | +2.6% | +15.1% | +6.6% | +9.4% | — |
| May 2, 2024 | AMC | -0.16 | -0.05 | +68.8% | 4.96 | +2.8% | -2.0% | -6.9% | -4.2% | -2.6% | -3.4% | — |
| Feb 29, 2024 | AMC | 0.30 | 0.26 | -13.3% | 6.22 | -14.0% | -5.3% | -13.8% | -16.7% | -11.1% | -7.6% | — |
| Nov 2, 2023 | AMC | 0.08 | 0.12 | +50.0% | 2.49 | -1.2% | +11.6% | +12.9% | +16.5% | +26.9% | +32.9% | — |
| Aug 3, 2023 | AMC | 0.07 | 0.10 | +42.9% | 3.52 | -4.0% | +8.5% | +11.9% | +16.2% | +15.9% | +14.5% | — |
| May 4, 2023 | AMC | 0.04 | 0.09 | +142.7% | 2.61 | +11.1% | +20.7% | +22.6% | +20.3% | +18.0% | +13.8% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 28 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.99 | $3.09 | +3.3% | +19.7% | +12.0% | +13.4% | +18.4% | +21.1% |
| Dec 23 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.75 | $2.77 | +0.7% | +2.2% | +9.8% | +14.5% | +12.0% | +13.8% |
| Nov 20 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.74 | $2.74 | +0.0% | +3.6% | +5.8% | +9.5% | +10.2% | +14.6% |
| Nov 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.03 | $3.39 | +11.9% | -5.0% | +8.9% | +5.9% | -2.0% | -1.3% |
| Aug 2 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.50 | $3.28 | -6.3% | +9.4% | +2.6% | +15.1% | +6.6% | +9.4% |
| Jul 26 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.94 | $3.99 | +1.3% | -2.8% | -8.4% | -8.1% | -8.9% | -11.2% |
| Jun 4 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.79 | $3.79 | +0.0% | -4.7% | -3.4% | -6.1% | -6.9% | -7.9% |
| Jun 3 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.85 | $3.91 | +1.6% | -1.6% | -6.2% | -4.9% | -7.5% | -8.3% |
| May 20 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.10 | $4.13 | +0.7% | +6.6% | +1.7% | +3.2% | -2.7% | -2.4% |
| May 3 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.96 | $5.10 | +2.8% | -2.0% | -6.9% | -4.2% | -2.6% | -3.4% |
| Mar 1 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.22 | $5.35 | -14.0% | -5.3% | -13.8% | -16.7% | -11.1% | -7.6% |
| Feb 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.36 | $6.34 | -0.3% | -2.4% | +16.4% | +9.9% | +11.8% | +6.8% |
| Sep 20 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.98 | $3.04 | +2.0% | -2.7% | -2.7% | -3.0% | -7.0% | -8.7% |
| Aug 4 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.52 | $3.38 | -4.0% | +8.5% | +11.9% | +16.2% | +15.9% | +14.5% |
| Jun 5 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.55 | $3.59 | +1.1% | +0.6% | -0.3% | +0.6% | -1.1% | -4.8% |
| May 5 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.61 | $2.90 | +11.1% | +20.7% | +22.6% | +20.3% | +18.0% | +13.8% |
| Mar 6 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.21 | $3.19 | -0.6% | -6.2% | -8.1% | -12.1% | -15.6% | -19.3% |
| Aug 31 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.75 | $2.80 | +1.8% | -2.5% | -4.7% | -6.2% | -10.2% | -9.5% |
| Aug 5 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.27 | $3.40 | +4.0% | +17.4% | +6.7% | +11.6% | +9.2% | +8.6% |
| May 6 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.24 | $2.39 | +6.7% | -11.2% | -25.0% | -18.8% | -26.8% | -21.9% |
| Sep 28 | Citigroup | Upgrade | Neutral → Buy | — | $7.12 | $7.64 | +7.3% | +2.5% | -1.3% | -1.5% | -9.1% | -11.9% |
| Aug 6 | Goldman Sachs | Maintains | Sell → Sell | — | $6.99 | $6.80 | -2.7% | +1.6% | -0.4% | +1.6% | +3.1% | +4.1% |
| Aug 6 | RBC Capital | Maintains | Sector Perform → Sector Perform | — | $6.99 | $6.80 | -2.7% | +1.6% | -0.4% | +1.6% | +3.1% | +4.1% |
| Aug 10 | Citigroup | Maintains | Neutral → Neutral | — | $10.27 | $10.12 | -1.5% | +2.6% | -2.3% | -3.4% | -3.5% | -4.3% |
| Aug 7 | SVB Leerink | Maintains | Market Perform → Market Perform | — | $10.38 | $10.38 | +0.0% | -1.1% | +1.5% | -3.4% | -4.4% | -4.5% |
| Jun 25 | BofA Securities | Maintains | Underperform → Underperform | — | $11.39 | $10.91 | -4.2% | -6.0% | -9.4% | -10.2% | -8.4% | -6.5% |
| May 20 | Cantor Fitzgerald | Maintains | Neutral → Neutral | — | $11.84 | $12.09 | +2.1% | +3.1% | +0.9% | -1.1% | -1.9% | -8.8% |
| Dec 6 | H.C. Wainwright | Maintains | Buy → Buy | — | $7.44 | $7.81 | +5.0% | +5.9% | +3.4% | +14.1% | +16.8% | +24.9% |
| Oct 8 | Goldman Sachs | Downgrade | Neutral → Sell | — | $10.07 | $8.88 | -11.8% | -21.9% | -24.0% | -28.0% | -29.2% | -32.7% |
| Aug 9 | Barclays | Maintains | Underweight → Underweight | — | $9.21 | $11.13 | +20.8% | +21.2% | +20.4% | +20.3% | +9.1% | +2.4% |
| May 10 | Cantor Fitzgerald | Downgrade | Overweight → Neutral | — | $30.02 | $18.70 | -37.7% | -38.6% | -43.7% | -41.5% | -44.7% | -43.8% |
| May 10 | Citigroup | Downgrade | Buy → Neutral | — | $30.02 | $18.70 | -37.7% | -38.6% | -43.7% | -41.5% | -44.7% | -43.8% |
| May 10 | Citi | Downgrade | Buy → Neutral | — | $30.02 | $18.70 | -37.7% | -38.6% | -43.7% | -41.5% | -44.7% | -43.8% |
| Mar 1 | Citigroup | Maintains | Buy → Buy | — | $27.81 | $36.85 | +32.5% | +40.0% | +44.1% | +38.9% | +31.8% | +37.3% |
| Jan 17 | Leerink Swann | Maintains | Market Perform → Perform | — | $25.33 | $25.11 | -0.9% | +0.6% | -0.4% | -6.5% | -3.0% | +3.4% |
| Jan 3 | Guggenheim | Downgrade | Buy → Neutral | — | $21.68 | $20.82 | -4.0% | -4.2% | -1.4% | +8.5% | +11.9% | +9.5% |
| Nov 19 | Goldman Sachs | Upgrade | Sell → Neutral | — | $23.58 | $24.19 | +2.6% | -2.1% | -1.9% | -0.1% | -1.4% | -0.0% |
| Nov 2 | Barclays | Downgrade | Equal Weight → Underweight | — | $38.60 | $24.00 | -37.8% | -48.0% | -40.8% | -42.0% | -40.2% | -39.9% |
| Nov 2 | JP Morgan | Maintains | Underweight → Underweight | — | $38.60 | $24.00 | -37.8% | -48.0% | -40.8% | -42.0% | -40.2% | -39.9% |
| Nov 2 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $38.60 | $24.00 | -37.8% | -48.0% | -40.8% | -42.0% | -40.2% | -39.9% |
| Oct 1 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $45.85 | $46.85 | +2.2% | +0.9% | +1.9% | +1.2% | -4.7% | -2.8% |
| Sep 18 | Citigroup | Maintains | Buy → Buy | — | $44.10 | $45.20 | +2.5% | +6.0% | +8.4% | +7.8% | +7.7% | +7.5% |
| Sep 17 | Goldman Sachs | Maintains | Sell → Sell | — | $47.00 | $45.55 | -3.1% | -6.2% | -0.5% | +1.7% | +1.2% | +1.1% |
| Aug 10 | JP Morgan | Maintains | Overweight → Overweight | — | $48.65 | $54.00 | +11.0% | -8.1% | -10.0% | -7.8% | -12.7% | -12.3% |
| Jun 28 | Citigroup | Maintains | Buy → Buy | — | $56.80 | $57.40 | +1.1% | -0.8% | +4.1% | +4.8% | +1.0% | +3.4% |
| Apr 12 | Barclays | Downgrade | Overweight → Equal Weight | — | $66.15 | $62.30 | -5.8% | +1.4% | +0.4% | -0.1% | +1.0% | -1.8% |
| Mar 9 | Stifel | Maintains | Buy → Buy | — | $80.85 | $82.45 | +2.0% | -0.1% | -1.7% | -8.7% | -8.2% | -8.0% |
| Mar 9 | Stifel Nicolaus | Maintains | Buy → Buy | — | $80.85 | $82.45 | +2.0% | -0.1% | -1.7% | -8.7% | -8.2% | -8.0% |
| Mar 2 | Barclays | Maintains | Overweight → Overweight | — | $61.75 | $61.95 | +0.3% | +15.1% | +23.6% | +23.5% | +29.1% | +30.9% |
| Jan 24 | BofA Securities | Maintains | Buy → Buy | — | $90.90 | $66.95 | -26.3% | -28.8% | -25.1% | -24.4% | -24.2% | -27.7% |
No insider trades available.
Data updated apr 26, 2026 6:53pm
· Source: massive.com